Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
It’s been a minute since I’ve wished you a good morning. Morning!
We’ve got some big news on Revolution Medicines’ pancreatic cancer treatment. But don’t miss GSK’s move to push an ovarian cancer ADC into five Phase 3 trials after striking early data. And Spyre Therapeutics released some competitive ulcerative colitis results. Continue to STAT+ to read the full story…